Article Text

other Versions

PDF
No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study
  1. Luciano Rinaldi1,
  2. Francesca Rinaldi1,
  3. Paola Perini1,
  4. Massimiliano Calabrese1,
  5. Dario Seppi1,
  6. Paola Grossi1,
  7. Irene Mattisi1,
  8. Luisa Barzon2,
  9. Carlo Mengoli2,
  10. Mariella Sanzari3,
  11. Giorgio Palú2,
  12. Paolo Gallo1
  1. 1Department of Neuroscience, Multiple Sclerosis Centre, First Clinic of Neurology, University Hospital of Padova, Padova, Italy
  2. 2Regional Reference Centre of Infectious Diseases, Microbiology and Virology Unit, University Hospital of Padova, Padova, Italy
  3. 3Central Hospital Laboratory, University Hospital of Padova, Padova, Italy
  1. Correspondence to Dr Francesca Rinaldi, Multiple Sclerosis Centre, First Clinic of Neurology, Department of Neuroscience, University Hospital of Padova, via Giustiniani 2, Padova 35128, Italy; dr.francesca.rinaldi{at}gmail.com

Abstract

Background and aim Natalizumab, used as therapy for multiple sclerosis (MS), has been associated with progressive multifocal leucoencephalopathy (PML), a potentially fatal disease caused by JC virus (JCV), which is not predictable by specific markers. This study evaluated whether JCV reactivation occurred in the urine and/or plasma in 42 MS patients treated with natalizumab over 18 months, and followed by a thorough monitoring programme.

Methods 42 patients (F/M: 24/18, mean age 34.4±8.9 years) were followed-up by: urine and plasma JCV-DNA PCR assay, immune cell subsets analysis, clinical and MRI evaluation, quality of life, fatigue and mood assessment.

Results JCV data. At baseline, 11/42 (26%) patients had JCV viruria, persistent at serial controls. One patient acquired viruria at month 1 and one patient at month 12. No patient had JCV viraemia at baseline; three patients acquired viraemic (one at month 6, one at month 13 (both transiently) and one at month 12 (persistently viraemic)). The prevalence of JCV in both urine and plasma did not change significantly from baseline to months 12 and 18. No patient had clinical or MRI evidence of PML. Immunological data. Circulating B cells showed greater expansion (300% increase in absolute number) since the first infusion. NK cell count doubled with no change in percentage while T cell count increased with a reduced percentage, reflecting a clear redistribution in the lymphocyte compartment. CD4+ and CD8+ T cells increased proportionally, with no change in their percentage. Clinical data. 27 patients (64%) were disease free after 1 year. A marked improvement in quality of life was reported by 72% of patients.

Conclusions No evidence of subclinical JCV reactivation was found in our natalizumab treated MS patients up to 18 months of therapy, notwithstanding the marked increase in circulating B cells observed. Moreover, the efficacy of natalizumab, its tolerability and the positive impact on quality of life were confirmed in this study.

  • MULTIPLE SCLEROSIS
  • VIROLOGY

Statistics from Altmetric.com

Footnotes

  • LR and FR contributed equally to this work.

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval This study was conducted with the approval of the local ethics committee of the University Hospital of Padova, Italy.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.